COMP <GO>
HAE vs MRK // GROSS PROFIT MARGIN
Haemonetics Corporation (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: HAE 3
— MRK 11
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $119.65 (-0.12%) • MKT CAP: $5.45B
gross-margins
59.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 59.00% | 74.80% | -15.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 20.70% | -12.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | 15.3x | +17.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | 3.42% | +1.36 | HAE | /fcf-yield <GO> |
| Operating Margin | 11.70% | 34.30% | -22.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 28.10% | -28.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 1.30% | -3.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.89 | 5.19 | -1.30 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 56.9 | +6.41 | HAE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.92 | +0.08 | HAE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 18.4x | +121.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.45B | $361.02B | -$355.57B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | MRK REV | HAE GROSS % | MRK GROSS % | HAE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $65.01B | 59.0% | 74.8% | $260.4M | $12.36B |
| FY 2024 | $1.36B | $64.17B | 55.0% | 76.3% | $142.4M | $18.10B |
| FY 2023 | $1.31B | $60.12B | 44.0% | 44.0% | $122.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
MRK // BETA 0.92